TruAlt Bioenergy Ltd
TRUALTTruAlt Bioenergy Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: profits are rising, but only 24% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (10 weeks in) while the P/E sits at the 66th percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +1,080.0% year on year, and 24% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
TruAlt Bioenergy Ltd trades at ₹423, in a confirmed uptrend and 10 weeks into that stage. That is −6.8% against its own 200-day average. It sits at 49% of a 52-week range of ₹320 to ₹532. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (4 weeks and counting).
Today the stock is in a confirmed uptrend — week 10 of stage 2, confirmed. At ₹423 it trades −6.8% versus its 200-day average and sits at 49% of its 52-week range (₹320–₹532).
Against the market, two honest reads. Cumulative: over the last 10 months the stock moved −20% while the NIFTY 500 moved +2% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (4 weeks and counting; last ahead the week of 2026-07-03) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
TruAlt Bioenergy Ltd trades at 23.2× P/E, mid-range by its own standards (66th percentile). Its long-run median P/E is 20.6×, measured across 0.8 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 23.2× is mid-range by its own standards (66th percentile), against a long-run median of 20.6× measured over 0.8 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
TruAlt Bioenergy Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 5 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −9.4% | +31.4% | — | — |
| Profit | −28.6% | +44.2% | — | — |
| EPS | −41.5% | +27.8% | — | — |
4-Factor Sector Score
40.8/100 — rank 21 of 36 in Miscellaneous · 63% evidence confidence
TruAlt Bioenergy Ltd scores 40.8 out of 100 against the 36 companies it is compared with in Miscellaneous, ranking 21. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 11.1 + 9.4 + 10.3 + 10 = 40.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
TruAlt Bioenergy Ltd reported ₹627 Cr of revenue in the Jun 26 quarter, +106.3% year on year. Over 3 years it has compounded at 31.4% a year. The last full year, FY26, came in at ₹1,728 Cr. The last four reported quarters add to ₹2,051 Cr.
FY26 revenue came in at ₹1,728 Cr (−9.4% on the year), capping 3 years at 31.4% compound. The latest quarter (Jun 26) printed ₹627 Cr, +106.3% year on year.
Pace check: the last four quarters averaged +18.3% growth against the decade's 31.4% — the current year is running slower than its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
TruAlt Bioenergy Ltd's operating margin is 21.0% in the Jun 26 quarter, +7.0 percentage points against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged 14.0% to 17.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 21.0%, +7.0 pp against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged 14.0%–17.0%.
Why the margin moved: operating margin went +7.5 pp year on year while gross margin went +9.8 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
TruAlt Bioenergy Ltd earned ₹59.0 Cr of net profit in the Jun 26 quarter, +1,080.0% year on year. Full-year FY26 profit was ₹105 Cr. The 3-year compound rate is 44.2%. That is 9.4% of the quarter's revenue. The same quarter a year earlier earned ₹5.0 Cr. 3 of the last 9 reported quarters were loss-making.
Jun 26 profit was ₹59.0 Cr, +1,080.0% year on year. On the full year, FY26 printed ₹105 Cr (−28.6%), and the 3-year compound rate is 44.2%.
Why profit moved: revenue contributed +106.3% and the margin +7.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +344.5% vs revenue +18.3%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 24% of TruAlt Bioenergy Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹−296 Cr of operating cash against ₹105 Cr of profit. After ₹510 Cr of capital spending, ₹−806 Cr was left as free cash.
FY26: operating cash of ₹−296 Cr against reported profit of ₹105 Cr, leaving free cash of ₹−806 Cr after ₹510 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 24% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 24%: the cash cycle stretched 242 days between FY23 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 242 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
TruAlt Bioenergy Ltd's cash conversion cycle runs 170 days in FY26, up from −72 days in FY23. Capital spending ran ₹1,151 Cr over the last 3 years. At FY26 sales of ₹1,728 Cr each day of that cycle holds about ₹4.7 Cr, so roughly ₹805 Cr sits inside the business at any moment.
FY26: debtors at 86 days, inventory at 173 days — roughly 5.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 170 days, looser than FY23's −72.
The full loop: cash goes out to suppliers and production on day 0; stock waits 173 days to sell; customers pay about 86 days after that; and suppliers themselves are paid at 89 days — netting out to the 170-day cycle.
In money terms: at FY26 sales of ₹1,728 Cr, each day of the cycle holds about ₹4.7 Cr — so the 170-day loop keeps roughly ₹805 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹1,151 Cr over the last 3 fiscal years against ₹210 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹68.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
TruAlt Bioenergy Ltd earns a ROCE of 11% in FY26. That is up from a trough of 11% in FY24. Return on invested capital clears the cost of that capital by −5.1 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 6.1% net margin on 0.46× asset turns.
FY26 ROCE is 11%, recovered from a FY24 trough of 11% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 6.1% net margin × 0.46× asset turns × 2.48× balance-sheet leverage ≈ 7.0% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 6.9% − 12.0% = a −5.1 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
TruAlt Bioenergy Ltd carries total debt of ₹1,652 Cr against shareholder equity of ₹1,578 Cr as of Mar 26, a debt-to-equity of 1.05. On the annual view that ratio went from 2.02 in FY25 to 1.05 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹1,652 Cr against shareholder equity of ₹1,578 Cr — a debt-to-equity of 1.05. On the annual view, debt-to-equity went from 2.02 (FY25) to 1.05 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of TruAlt Bioenergy Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — .
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
TruAlt Bioenergy Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1IIRM Holdings India Ltd526530 | 66.2/100Favorable setup71% evidence | LEADER | 17.7/35 Revenue 14.9% · PAT 12.7% · OPM change 8.4 pp 83% evidence | 19.1/25 ROCE 20.4% · OPM 24.8% 76% evidence | 9.7/20 P/E 40.4× · PEG — 15% evidence | 19.7/20 RS sector 49.6% · RS bench 53.5% · 1Y 67.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 19.1 + 9.7 + 19.7 = 66.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Sagility LtdSAGILITY | 66.1/100Favorable setup87% evidence | TURNING | 24.4/35 Revenue 29.4% · PAT 49.3% · OPM change 0 pp 100% evidence | 15.5/25 ROCE 13.4% · OPM 22% 100% evidence | 14.2/20 P/E 19.8× · PEG 1.05 65% evidence | 12.0/20 RS sector 7.2% · RS bench -5% · 1Y -1.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 24.4 + 15.5 + 14.2 + 12 = 66.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Gulshan Polyols LtdGULPOLY | 65.2/100Favorable setup75% evidence | TURNING | 24.8/35 Revenue 35.2% · PAT 87% · OPM change 4.3 pp 59% evidence | 12.3/25 ROCE 6.3% · OPM 8% 95% evidence | 10.5/20 P/E 28.9× · PEG — 50% evidence | 17.6/20 RS sector 16.1% · RS bench 19.4% · 1Y 16.1%10 of 12 weeks ahead 100% evidence |
| Exact sum: 24.8 + 12.3 + 10.5 + 17.6 = 65.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Exhicon Events Media Solutions Ltd543895 | 64.4/100Thin evidence · provisional60% evidence | ASLEEP | 19.3/35 Revenue 100% · PAT 100% · OPM change 0 pp 48% evidence | 20.1/25 ROCE 29.5% · OPM 28% 76% evidence | 13.6/20 P/E 19.2× · PEG — 50% evidence | 11.4/20 RS sector 2.2% · RS bench -1.2% · 1Y -7.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 19.3 + 20.1 + 13.6 + 11.4 = 64.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5GMR Airports LtdGMRAIRPORT | 59.8/100Mixed-positive evidence71% evidence | BREAKING OUT | 22.8/35 Revenue 42.2% · PAT 100% · OPM change 2 pp 65% evidence | 14.2/25 ROCE 11.6% · OPM 37% 100% evidence | 8.6/20 P/E 534× · PEG — 15% evidence | 14.2/20 RS sector 3.3% · RS bench 6.5% · 1Y 17.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 22.8 + 14.2 + 8.6 + 14.2 = 59.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Aeroflex Enterprises LtdAEROENTER | 59.3/100Mixed-positive evidence83% evidence | LEADER | 16.8/35 Revenue 20.4% · PAT 4.9% · OPM change 1 pp 83% evidence | 16.0/25 ROCE 12.6% · OPM 18% 95% evidence | 8.1/20 P/E 20.9× · PEG — 50% evidence | 18.4/20 RS sector 24.8% · RS bench 28.1% · 1Y 16%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 16 + 8.1 + 18.4 = 59.3 · Decision use: Price leads the evidence: RS versus the benchmark is 28.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 7Global Education LtdGLOBAL | 59.3/100Mixed-positive evidence76% evidence | ASLEEP | 16.6/35 Revenue 29.9% · PAT -5.5% · OPM change 7.5 pp 83% evidence | 19.4/25 ROCE 29.2% · OPM 47% 95% evidence | 10.8/20 P/E 20× · PEG — 15% evidence | 12.5/20 RS sector 12.5% · RS bench 15.9% · 1Y 56.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 19.4 + 10.8 + 12.5 = 59.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Take Solutions LtdTAKE | 58.9/100Mixed-positive evidence63% evidence | 25.1/35 Revenue — · PAT 100% · OPM change 2932.2 pp 57% evidence | 8.3/25 ROCE 11.2% · OPM — 80% evidence | 8.5/20 P/E 3222× · PEG — 15% evidence | 17.0/20 RS sector 68% · RS bench 71.4% · 1Y 305.2%11 of 12 weeks ahead to 2026-05-03 100% evidence | |
| Exact sum: 25.1 + 8.3 + 8.5 + 17 = 58.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9R K Swamy LtdRKSWAMY | 58.5/100Mixed-positive evidence61% evidence | TURNING | 22.5/35 Revenue 15.9% · PAT 21.1% · OPM change 3 pp 83% evidence | 16.9/25 ROCE 12.3% · OPM 22% 95% evidence | 10.4/20 P/E 21.2× · PEG — 15% evidence | 8.7/20 RS sector — · RS bench -11.2% · 1Y —3 of 3 weeks ahead 25% evidence |
| Exact sum: 22.5 + 16.9 + 10.4 + 8.7 = 58.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Jai Corp LtdJAICORPLTD | 57.6/100Mixed-positive evidence70% evidence | ASLEEP | 24.1/35 Revenue -0.6% · PAT 100% · OPM change 5 pp 83% evidence | 15.3/25 ROCE 13.3% · OPM 13% 95% evidence | 11.5/20 P/E 10.4× · PEG — 15% evidence | 6.7/20 RS sector -8.2% · RS bench -18.9% · 1Y -1.9%4 of 10 weeks ahead 70% evidence |
| Exact sum: 24.1 + 15.3 + 11.5 + 6.7 = 57.6 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -8.2% and the one-year return is -1.9%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 11Aegis Vopak Terminals LtdAEGISVOPAK | 56.0/100Thin evidence · provisional56% evidence | TURNING | 21.4/35 Revenue 25.6% · PAT 76.7% · OPM change 2 pp 83% evidence | 13.4/25 ROCE 7.6% · OPM 74% 76% evidence | 9.1/20 P/E 104× · PEG — 15% evidence | 12.1/20 RS sector — · RS bench 22% · 1Y 13%5 of 10 weeks ahead 25% evidence |
| Exact sum: 21.4 + 13.4 + 9.1 + 12.1 = 56 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Parin Enterprises LtdPARIN | 54.3/100Mixed-positive evidence63% evidence | BREAKING OUT | 19.7/35 Revenue 100% · PAT 100% · OPM change -3 pp 48% evidence | 11.7/25 ROCE 10.8% · OPM 9% 95% evidence | 9.0/20 P/E 123× · PEG — 15% evidence | 13.9/20 RS sector 13.1% · RS bench 16.5% · 1Y 94.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 11.7 + 9 + 13.9 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Inox Green Energy Services LtdINOXGREEN | 50.7/100Mixed-positive evidence65% evidence | ASLEEP | 24.7/35 Revenue 24.6% · PAT 100% · OPM change 0.5 pp 83% evidence | 9.5/25 ROCE 8.4% · OPM -4.1% 76% evidence | 9.3/20 P/E 66× · PEG — 15% evidence | 7.2/20 RS sector -8.6% · RS bench -8.4% · 1Y -1.1%6 of 10 weeks ahead 70% evidence |
| Exact sum: 24.7 + 9.5 + 9.3 + 7.2 = 50.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Eveready Industries India LtdEVEREADY | 48.3/100Mixed-negative evidence90% evidence | TURNING | 17.6/35 Revenue 8.2% · PAT 100% · OPM change 0 pp 88% evidence | 14.9/25 ROCE 17.2% · OPM 9% 100% evidence | 8.1/20 P/E 24.9× · PEG 2.1 100% evidence | 7.7/20 RS sector -9.5% · RS bench -3% · 1Y -19.9%4 of 10 weeks ahead 70% evidence |
| Exact sum: 17.6 + 14.9 + 8.1 + 7.7 = 48.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15TCC Concept LtdTCC | 47.3/100Mixed-negative evidence81% evidence | ASLEEP | 17.3/35 Revenue 100% · PAT 51.1% · OPM change -45 pp 95% evidence | 11.4/25 ROCE 5.7% · OPM 36% 95% evidence | 14.1/20 P/E 20.9× · PEG — 50% evidence | 4.5/20 RS sector -17.6% · RS bench -35% · 1Y -44.2%0 of 11 weeks ahead 70% evidence |
| Exact sum: 17.3 + 11.4 + 14.1 + 4.5 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16GKW LtdGKWLIMITED | 46.7/100Mixed-negative evidence63% evidence | ASLEEP | 20.7/35 Revenue -2.1% · PAT 87.5% · OPM change 2160.4 pp 83% evidence | 6.7/25 ROCE 0.5% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.3/20 RS sector -0.9% · RS bench -5% · 1Y -8.8%4 of 10 weeks ahead 70% evidence |
| Exact sum: 20.7 + 6.7 + 10 + 9.3 = 46.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Prozone Realty LtdPROZONER | 43.4/100Mixed-negative evidence68% evidence | ASLEEP | 21.2/35 Revenue 9.2% · PAT 100% · OPM change 23 pp 62% evidence | 11.2/25 ROCE 6.1% · OPM 34.5% 95% evidence | 9.6/20 P/E 59.4× · PEG — 15% evidence | 1.4/20 RS sector -23% · RS bench -20.5% · 1Y -0.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 11.2 + 9.6 + 1.4 = 43.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Jindal Photo LtdJINDALPHOT | 41.5/100Mixed-negative evidence67% evidence | ASLEEP | 14.6/35 Revenue 100% · PAT -80% · OPM change -1015.9 pp 83% evidence | 5.9/25 ROCE -1.4% · OPM -932.6% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.0/20 RS sector 6.3% · RS bench -13.8% · 1Y 23.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 14.6 + 5.9 + 10 + 11 = 41.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Aqylon Nexus LtdAQYLON | 41.4/100Thin evidence · provisional54% evidence | ASLEEP | 12.7/35 Revenue 30.8% · PAT -52.5% · OPM change -2377.7 pp 48% evidence | 16.8/25 ROCE 39.2% · OPM — 80% evidence | 8.7/20 P/E 168.9× · PEG — 15% evidence | 3.2/20 RS sector -41.3% · RS bench -74.1% · 1Y -68.5%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.7 + 16.8 + 8.7 + 3.2 = 41.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Kaveri Seed Company LtdKSCL | 41.2/100Mixed-negative evidence82% evidence | ASLEEP | 18.1/35 Revenue 15.9% · PAT 5% · OPM change 3 pp 65% evidence | 12.6/25 ROCE 18.8% · OPM -15% 100% evidence | 5.1/20 P/E 13.6× · PEG 2.98 100% evidence | 5.4/20 RS sector -17.2% · RS bench -18.7% · 1Y -30.4%5 of 11 weeks ahead 70% evidence |
| Exact sum: 18.1 + 12.6 + 5.1 + 5.4 = 41.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21TruAlt Bioenergy Ltdthis pageTRUALT | 40.8/100Mixed-negative evidence63% evidence | ASLEEP | 11.1/35 Revenue 1.8% · PAT -8.1% · OPM change 7 pp 100% evidence | 9.4/25 ROCE 10.8% · OPM 21% 100% evidence | 10.3/20 P/E 23.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 12 weeks ahead 0% evidence |
| Exact sum: 11.1 + 9.4 + 10.3 + 10 = 40.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Delta Corp LtdDELTACORP | 38.6/100Mixed-negative evidence77% evidence | ASLEEP | 11.2/35 Revenue -6.5% · PAT -66.4% · OPM change -5 pp 83% evidence | 9.6/25 ROCE 5% · OPM 17% 95% evidence | 12.5/20 P/E 18.9× · PEG — 50% evidence | 5.3/20 RS sector -18.1% · RS bench -11.6% · 1Y -28.9%6 of 10 weeks ahead 70% evidence |
| Exact sum: 11.2 + 9.6 + 12.5 + 5.3 = 38.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Shipping Corporation of India Land & Assets LtdSCILAL | 33.7/100Adverse evidence68% evidence | ASLEEP | 15.6/35 Revenue 27.3% · PAT 100% · OPM change -284.4 pp 62% evidence | 4.7/25 ROCE 1.3% · OPM -349.6% 95% evidence | 9.2/20 P/E 66.6× · PEG — 15% evidence | 4.2/20 RS sector -15.5% · RS bench -12.7% · 1Y -19.8%3 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 4.7 + 9.2 + 4.2 = 33.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Unitech LtdUNITECH | 32.0/100Adverse evidence65% evidence | ASLEEP | 12.8/35 Revenue 59% · PAT 5% · OPM change -584 pp 62% evidence | 6.1/25 ROCE 0.1% · OPM 184% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.1/20 RS sector -27.3% · RS bench -24.8% · 1Y -42.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 12.8 + 6.1 + 10 + 3.1 = 32 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Stanley Lifestyles LtdSTANLEY | 31.5/100Adverse evidence70% evidence | TURNING | 8.4/35 Revenue -1.6% · PAT -55.5% · OPM change -5.2 pp 83% evidence | 10.3/25 ROCE 6.4% · OPM 14.9% 95% evidence | 9.5/20 P/E 62.7× · PEG — 15% evidence | 3.3/20 RS sector -43.7% · RS bench -23.7% · 1Y -53.6%3 of 10 weeks ahead 70% evidence |
| Exact sum: 8.4 + 10.3 + 9.5 + 3.3 = 31.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26RattanIndia Enterprises LtdRTNINDIA | 29.3/100Adverse evidence62% evidence | ASLEEP | 13.8/35 Revenue 5.4% · PAT -80% · OPM change 19 pp 65% evidence | 1.6/25 ROCE -4.8% · OPM -6% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.9/20 RS sector -32.1% · RS bench -23% · 1Y -45%6 of 10 weeks ahead 70% evidence |
| Exact sum: 13.8 + 1.6 + 10 + 3.9 = 29.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Embassy Developments LtdEMBDL | 26.2/100Adverse evidence68% evidence | BREAKING OUT | 4.3/35 Revenue -20.6% · PAT -80% · OPM change -76.9 pp 83% evidence | 3.6/25 ROCE -2.4% · OPM -76% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.3/20 RS sector -17.2% · RS bench -14.6% · 1Y -45.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 4.3 + 3.6 + 10 + 8.3 = 26.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Central Mine Planning & Design Institute LtdCMPDI | 62.2/100Thin evidence · provisional38% evidence | TURNING | 22.3/35 Revenue — · PAT — · OPM change 8 pp 32% evidence | 19.8/25 ROCE 38.1% · OPM 30% 95% evidence | 10.1/20 P/E 26.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 3 weeks ahead 0% evidence |
| Exact sum: 22.3 + 19.8 + 10.1 + 10 = 62.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29FlySBS Aviation LtdFLYSBS | 54.7/100Thin evidence · provisional41% evidence | TURNING | 15.4/35 Revenue — · PAT — · OPM change -8 pp 26% evidence | 18.9/25 ROCE 32.5% · OPM 21% 95% evidence | 11.4/20 P/E 13.3× · PEG — 15% evidence | 9.0/20 RS sector — · RS bench -6.8% · 1Y 4.4%3 of 10 weeks ahead 25% evidence |
| Exact sum: 15.4 + 18.9 + 11.4 + 9 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Qualitek Labs Ltd544091 | 53.7/100Thin evidence · provisional29% evidence | 17.3/35 Revenue — · PAT — · OPM change -3 pp 7% evidence | 15.0/25 ROCE 11.9% · OPM 26% 76% evidence | 9.8/20 P/E 33.6× · PEG — 15% evidence | 11.6/20 RS sector — · RS bench 9.1% · 1Y — 25% evidence | |
| Exact sum: 17.3 + 15 + 9.8 + 11.6 = 53.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 31Shree Vasu Logistics LtdSVLL | 51.9/100Thin evidence · provisional48% evidence | TURNING | 18.4/35 Revenue — · PAT — · OPM change 2.6 pp 19% evidence | 15.7/25 ROCE 12.9% · OPM 29% 95% evidence | 8.9/20 P/E 144× · PEG — 15% evidence | 8.9/20 RS sector -16.1% · RS bench 5.1% · 1Y -8.1%9 of 10 weeks ahead 70% evidence |
| Exact sum: 18.4 + 15.7 + 8.9 + 8.9 = 51.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 32Maagh Advertising & Marketing Services Ltd543624 | 49.6/100Thin evidence · provisional35% evidence | 18.3/35 Revenue — · PAT — · OPM change 275.6 pp 32% evidence | 9.0/25 ROCE -0.4% · OPM 55.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.3/20 RS sector — · RS bench 37% · 1Y —7 of 9 weeks ahead to 2025-03-19 25% evidence | |
| Exact sum: 18.3 + 9 + 10 + 12.3 = 49.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Indiqube Spaces LtdINDIQUBE | 49.3/100Thin evidence · provisional46% evidence | ASLEEP | 20.9/35 Revenue 36.9% · PAT 23.6% · OPM change 5 pp 62% evidence | 9.6/25 ROCE 6.4% · OPM 62% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.8/20 RS sector — · RS bench -9.8% · 1Y -20.2%2 of 10 weeks ahead 25% evidence |
| Exact sum: 20.9 + 9.6 + 10 + 8.8 = 49.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 34Anzen India Energy Yield Plus TrustANZEN | 47.7/100Thin evidence · provisional46% evidence | ASLEEP | 17.4/35 Revenue 76.8% · PAT 100% · OPM change -9 pp 62% evidence | 8.9/25 ROCE 3.3% · OPM 75.5% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.4/20 RS sector — · RS bench 5.7% · 1Y 9.6%4 of 10 weeks ahead 25% evidence |
| Exact sum: 17.4 + 8.9 + 10 + 11.4 = 47.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 35Shree Rama Newsprint LtdRAMANEWS | 44.6/100Thin evidence · provisional46% evidence | 14.1/35 Revenue -20% · PAT 69.8% · OPM change -8 pp 40% evidence | 5.7/25 ROCE 1.9% · OPM 8% 71% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.8/20 RS sector 7.4% · RS bench 10.5% · 1Y 8.8%11 of 12 weeks ahead to 2026-04-19 70% evidence | |
| Exact sum: 14.1 + 5.7 + 10 + 14.8 = 44.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 36Tandhan Industries Ltd512062 | 42.6/100Thin evidence · provisional33% evidence | TURNING | 16.3/35 Revenue — · PAT -80% · OPM change — 50% evidence | 6.3/25 ROCE -0.3% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —4 of 4 weeks ahead 0% evidence |
| Exact sum: 16.3 + 6.3 + 10 + 10 = 42.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is TruAlt Bioenergy Ltd's share price today?
TruAlt Bioenergy Ltd trades at ₹423. The company is valued at ₹3,627 Cr. The stock sits at 49% of its 52-week range of ₹320–₹532, −6.8% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 10 weeks in. — as of 31 July 2026.
What were TruAlt Bioenergy Ltd's latest quarterly results?
TruAlt Bioenergy Ltd reported revenue of ₹627 Cr and net profit of ₹59.0 Cr for the Jun 26 quarter. Revenue rose 106.3% and profit rose 1,080.0% year on year. Earnings per share were ₹6.66. The operating margin was 21.0%, 7.0 pp higher than a year earlier. — as of 31 July 2026.
What is TruAlt Bioenergy Ltd's revenue?
TruAlt Bioenergy Ltd reported revenue of ₹627 Cr in the Jun 26 quarter, +106.3% year on year. For the full FY26 fiscal year, revenue was ₹1,728 Cr (−9.4%). Over the last 3 years revenue compounded at 31.4% a year. — as of 31 July 2026.
What is TruAlt Bioenergy Ltd's profit?
TruAlt Bioenergy Ltd earned ₹59.0 Cr of net profit in the Jun 26 quarter, +1,080.0% year on year. Full-year FY26 profit was ₹105 Cr. The operating margin ran 21.0% in the latest quarter. — as of 31 July 2026.
What is TruAlt Bioenergy Ltd's market cap?
TruAlt Bioenergy Ltd's market capitalisation is ₹3,627 Cr at a share price of ₹423. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is TruAlt Bioenergy Ltd's P/E ratio?
TruAlt Bioenergy Ltd trades at a P/E of 23.2×, at the 66th percentile of its own 1-year range, against a long-run median of 20.6×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does TruAlt Bioenergy Ltd pay a dividend?
No — TruAlt Bioenergy Ltd has recorded a dividend payout of 0% of profit in each of its last 4 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 31 July 2026.
Is TruAlt Bioenergy Ltd overvalued?
On its own history, TruAlt Bioenergy Ltd looks expensive against its own history: its P/E of 23.2× sits at the 66th percentile of its 1-year range (long-run median 20.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is TruAlt Bioenergy Ltd growing?
Yes — TruAlt Bioenergy Ltd is growing: latest-quarter revenue +106.3% year on year, profit +1,080.0%, and the margin +7.0 pp at 21.0%. The 3-year compound rates are 31.4% (revenue) and 44.2% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is TruAlt Bioenergy Ltd performing?
TruAlt Bioenergy Ltd is in a confirmed uptrend, 10 weeks in. Its latest quarter's revenue rose 106.3% and profit rose 1,080.0% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
Is TruAlt Bioenergy Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 10 of stage 2), trading −6.8% versus its 200-day average and at 49% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is TruAlt Bioenergy Ltd beating the market?
Not lately — on a trailing-13-week view TruAlt Bioenergy Ltd is currently behind the NIFTY 500 (4 weeks and counting; last ahead the week of 2026-07-03), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10 months the stock moved −20% against the NIFTY 500's +2% — behind the index over the full window. — as of 31 July 2026.
Will TruAlt Bioenergy Ltd's share price go up?
This page publishes no price forecast for TruAlt Bioenergy Ltd. What it measures instead: the share price is ₹423, the price is in a confirmed uptrend 10 weeks in. Its P/E of 23.2× sits at the 66th percentile of its own 1-year range. — as of 31 July 2026.
Who owns TruAlt Bioenergy Ltd?
Promoters hold 70.5% of TruAlt Bioenergy Ltd, foreign institutions 0.6%, domestic institutions 8.4% and the public 20.5% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does TruAlt Bioenergy Ltd have too much debt?
It carries real leverage — TruAlt Bioenergy Ltd's debt-to-equity is 1.09, and operating profit covers the interest bill 2×. FY26 borrowings were ₹1,652 Cr against equity of ₹1,521 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is TruAlt Bioenergy Ltd's capex?
TruAlt Bioenergy Ltd spent ₹1,151 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹510 Cr, with ₹68.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is TruAlt Bioenergy Ltd's cash flow?
TruAlt Bioenergy Ltd generated ₹−296 Cr of operating cash flow in FY26 and ₹−806 Cr of free cash flow after ₹510 Cr of capital spending. Reported profit that year was ₹105 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is TruAlt Bioenergy Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 24% of TruAlt Bioenergy Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹−296 Cr against reported profit of ₹105 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 31 July 2026.
Where is TruAlt Bioenergy Ltd in its business cycle?
TruAlt Bioenergy Ltd's FY26 operating margin was 17.0%, against a 4-year band of 14.0%–17.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 21.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the TruAlt Bioenergy Ltd story?
The sharpest disagreement: profits are rising, but only 24% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is TruAlt Bioenergy Ltd a stock worth studying right now?
This is not investment advice. The machine read: TruAlt Bioenergy Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.